iRhythm Technologies Signals Profitable Growth Amid Overhangs

Irhythm Technologies ((IRTC)) has held its Q1 earnings call. Read on for the main highlights of the call.

iRhythm Technologies’ latest earnings call struck an optimistic tone, as strong top-line momentum and expanding margins outweighed lingering regulatory and legal risks. Management highlighted robust demand, improving efficiency, and a fortified balance sheet, while acknowledging ongoing net losses, negative early-year cash flow, and policy uncertainty that could still unsettle sentiment.

Strong Revenue Growth and Upward Guidance

iRhythm posted Q1 2026 revenue of $199.4 million, up 25.7% from a year earlier, underscoring sustained demand for its cardiac monitoring platform. On the back of this beat, the company lifted full-year 2026 revenue guidance to $875 million–$885 million and projected Q2 revenue of $218 million–$220 million, implying mid‑teens to high‑teens growth.

Material Profitability Improvement

Profitability trends continued to inflect positively, with Q1 adjusted EBITDA reaching $14.1 million, or 7.1% of revenue, an 880 basis point improvement year over year. Management also raised full‑year adjusted EBITDA margin guidance to 12%–13%, with Q2 margins expected between 11.5% and 12.5%, signaling further operating leverage.

Gross Margin Expansion

Gross margin in Q1 expanded to 70.9%, up 210 basis points from the prior year, driven by manufacturing automation and efficiency gains in clinical operations. Scale benefits also contributed, indicating that higher volumes are dropping through more cleanly to profitability as the business grows.

Large Cash Balance Provides Flexibility

The company closed Q1 with $549.6 million in cash, cash equivalents, and marketable securities, giving it substantial financial flexibility. Management emphasized this balance as a key enabler of continued investment in product innovation, commercial expansion, and international initiatives despite ongoing net losses.

Broad Clinical Adoption and Evidence Base

iRhythm’s Zio platform is increasingly underpinned by clinical data, with more than 140 publications and recent presentations at major cardiology meetings supporting its diagnostic performance. Ongoing head‑to‑head and real‑world studies are designed to reinforce Zio’s superiority and its potential to reduce downstream healthcare costs.

Scale, Integration, and Channel Momentum

Digital integration continues to deepen, with roughly 53% of the company’s volume now flowing through EHR‑integrated accounts and over three‑quarters of its top 100 customers integrated. New‑store accounts open less than a year drove about 64% of year‑over‑year volume growth, and U.S. home enrollment represented roughly 23% of total volume.

AI and Product Roadmap Progress

Leveraging more than 3 billion hours of curated ECG data, iRhythm has submitted a next‑generation AI algorithm for regulatory clearance and expects a decision later this year. The company believes this algorithm could cut technician review time by up to half, boosting efficiency and margins, while it reiterated plans to launch its next‑generation MCT product in the first half of 2027.

International and Adjacent Market Traction

Internationally, the U.K. delivered the strongest quarter in the company’s history, highlighting the appeal of Zio outside the U.S. In Japan, a modest supplemental reimbursement increase for longer‑duration monitoring was framed as an encouraging early marker as the company pursues more substantial premium reimbursement.

GAAP and Adjusted Net Losses Persist

Despite improving fundamentals, iRhythm remains unprofitable on a net income basis, reporting a Q1 GAAP net loss of $13.9 million, or $0.43 per diluted share. Adjusted net loss narrowed to $11.3 million, or $0.35 per share, from $30.3 million a year earlier, marking progress but underscoring that full earnings normalization is still ahead.

Negative Free Cash Flow in Q1

Free cash flow stayed in the red at negative $33 million for Q1 2026, which management attributed largely to normal seasonality, annual compensation payments, and working capital timing. The company expects free cash flow to improve over the course of the year and be more heavily skewed to the second half, echoing prior patterns.

Regulatory and Legal Overhangs

Regulatory and legal issues remain a key overhang, including an outstanding FDA warning letter even though remediation work is complete and an independent review found no material issues. A separate inquiry remains open, with limited recent activity, leaving investors to weigh the tail risks from potential outcomes that remain uncertain in both scope and timing.

Rising Operating Costs and Litigation-Related Expenses

Adjusted operating expenses climbed 9.3% year over year to $153.5 million, reflecting higher volume‑related costs, legal spending, and investments to fuel future growth. While this spending supports commercialization and innovation, it also tempers near‑term margin expansion and underscores the importance of continued revenue and efficiency gains.

Policy and Coverage Uncertainty

Proposed coverage language from several Medicare contractors could reclassify many monitoring cases into a more stringent category that requires continuous 24‑hour monitoring. Management warned that, as currently written, such changes could materially shift market dynamics and create near‑term reimbursement ambiguity, though timing and final provisions are still unclear.

Guidance and Forward-Looking Outlook

Looking ahead, iRhythm now forecasts 2026 revenue of $875 million–$885 million, up roughly 17%–18% from 2025, with Q2 revenue guided to $218 million–$220 million and pricing expected to be stable. The company also targets full‑year adjusted EBITDA margins between 12% and 13%, driven by ongoing gross‑margin gains and efficiency initiatives, and expects free cash flow to improve versus 2025, particularly in the back half.

iRhythm’s earnings call painted a picture of a growth company steadily improving its economic profile while navigating meaningful external risks. For investors tracking the stock, the combination of strong volume growth, widening margins, and a solid cash cushion is encouraging, but the outcome of regulatory, legal, and reimbursement developments will likely remain a decisive swing factor.